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ABSTRACT 
Myostatin (mstn) belongs to the TGF-~ family and is best known as a 
negative regulator of muscle growth. Hypermuscularity in mstn knockout mice 
has been widely recognized and numerous mstn inhibitors are in development to 
treat sarcopenia associated with aging and muscle wasting associated with 
chronic illness. To determine the health impact of long term mstn deficiency on 
physical performance, myostatin null (mstn-/-) mice were studied at three aging 
time points (5, 15, 22 months). Long term complete inhibition of myostatin was 
hypothesized to prevent the decline in physical performance expected with aging. 
The data disproves this hypothesis. While increased muscle was observed in the 
mstn-/- and the mice demonstrated an expected grip strength advantage at 5 
months, by 15 and 22 months the overall grip strength was reduced with no 
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significant difference compared to controls. Horizontal and vertical ambulatory 
activity at each aging time point showed a significantly decreased or a decreased 
trend when compared with age-matched wild type controls. Furthermore, the 
mstn-/- mice treadmill endurance was significantly less at 5 and 22 months and 
demonstrated a decreased trend at 15 months when compared to age-matched 
controls. Overall, long term myostatin deletion does not aid in the maintenance of 
overall physical performance as the animal ages. Since prior studies had also 
shown that myostatin affected both bone mass, cartilage development and 
skeletal tissue repair the effects of myostatin deletion were next examined 
relative to skeletal tissue structure and function. Micro Computerized 
Tomography (MicroCT) analysis showed increased size and ossification of the 
meniscus surrounding the knee, ectopic ossification surrounding the tarsal bones 
and extra ossification in joints between manus carpal bones in the myostatin null 
mice. These studies showed that this ectopic calcification increased with aging. 
Corresponding histology of 22 month old mstn-/- mice demonstrated increased 
fibrocartilage proliferation of the meniscus and loss of the tibial articular cartilage. 
Our current data suggests long term complete deletion of myostatin increases 
proliferation and differentiation of fibrocartilage and reduces articular cartilage 
maintenance leading to impaired joint function and an overall reduction in 
physical performance. 
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I. Introduction 
Aging and Frailty 
Aging is the continued process of changes that occur in tissues or organs 
of the body that lead to a decline in function and death.1 In 1990, the American 
Medical Association published a white paper stating "one of the most important 
tasks that the medical community faces today is to prepare for the problems in 
caring for the elderly in the 1990s and the early 21 51 century". 2 The population 
aged 65 or older has increased 9% from 1900 to 2010 and is predicted to expand 
to 20% of the total population by 2030. 3 Not all individuals who age will 
experience and exhibit physiological decline at the same rate. Some individuals 
may begin to display acute or chronic illness early in aging and others may age 
"successfully" and not have any physical ailments into their late age. 
Frailty. Gerontologists have begun to understand how an individual ages 
"successfully". Successful aging can be defined as having a low probability of 
disease, disability related to disease, maintaining high cognitive and physical 
function, and actively engaging in life. 4 One aspect of aging that investigators 
have studied is the concept of frailty. In the field of gerontology, the definition of 
"frail" elderly has been debated since the 1980s. In 1988, Woodhouse defined 
frail elderly as individuals more than 65 years old who are dependent on others 
for activities of daily living, and are often in institutional care. 5 Since Woodhouse 
defined frailty the definition has been associated with both disability and 
comorbidity. Disability is defined "as difficulty in carrying out activities essential 
to independent living, including essential roles, tasks needed for self-care and 
living independently in a home, and desired activities important to one's quality of 
life".6 Disability is estimated in 20-30% of adults aged 70 years or older who live 
in the community. 7 Comorbidity is defined as the concurrent presence of two or 
more medically diagnosed diseases in the same individual. Studies show 35.3% 
of the 65-79 year old population has two or more diseases.7 At 80 years and 
older 70.2% have two or more diseases.7 Comorbidity also increases the risk of 
disability and mortality.8-13 Although previous definitions of frailty have included 
comorbidity and disability, studies demonstrate that comorbidity and frailty are 
both independent risk factors for disability. 11 -13 As demonstrated in Figure 1, 
there is definitive overlap with comorbidity, frailty and disability; however each 
has a significant proportion that does not impact the other. 
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Figure 1. Overlaps of Disability, Comorbidity, and Frailty. 
Prevalence and overlap of these conditions in community-
dwelling men and women 65 years and older. The percent 
describes the proportion of individuals who were frail , who had 
comorbidity and /or disability, or neither. +n=368 frail 
participants overall. *n=2576 comorbid participants with 2 or 
more of following 9 diseases: angina, arthritis, congestive heart 
failure , claudication, myocardial infarction, cancer, diabetes, 
hypertension, chronic obstructive pulmonary disease. **n=363 
participants with an activity of daily living disability 
Investigators sought to develop a definition that would organize a 
phenotype of frailty because no standardized definition had been previously 
established .6 The criteria included are clear physiologic measurements that can 
define the spectrum of frailty . Table 1 demonstrates how Fried et al. 
characterized frailty and the measurements used. In our study, we measured 
body and muscle mass to assess changes in body and muscle weight, grip 
strength to assess weakness, treadmill endurance to assess level of exhaustion, 
and ambulatory activity to assess level of activity, all to understand how these 
may change over time in our aging model. 
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A. Characteristics of Frailty 
Shrinking: Weight loss (unintentional) 
Sarcopenia (loss of muscle mass) 
Weakness 
Poor endurance, Exhaustion 
Slowness 
Low activity 
Adapted from Fried et al. 200 I 
Used with Permission O xford University Press 
Table 1. Operationalizing a Phenotype of Frailty. The 
phenotype of frailty was identified by the presence of 
three or more of the described characteristics of frailty. 
Sarcopenia and dynapenia. Aging is associated with the inevitable 
decline of body composition including the musculoskeletal system. In 1989 
Rosenberg coined the term sarcopenia to describe in the elderly this age related 
muscle mass decline.14 The New Mexico Elder Health Survey reports 20% of 
men and 25% of women between age 70 and 75 years and 50% of men and 
40% of women over age 80 years have sarcopenia.15 Sarcopenia is a predictor of 
disability in the elderly. 16-18 The term dynapenia refers to the associated loss of 
muscle strength during aging.19 Sarcopenia is one factor that may lead to 
dynapenia, although the loss of muscle strength may also be due to alterations in 
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contractile properties or neuromuscular function.19 With a growing elderly 
population, it is of importance to develop treatments to maintain muscle mass 
and strength to reduce the risk of disability. 
To combat impairments in muscle mass and strength, which are 
associated with mobility and physical function limitations, exercise training has 
been proven as the most efficacious. 20 Resistance exercise training increases 
muscle strength but has variable effects on muscle mass. 21 Although resistance 
training has shown to be effective in increasing muscle strength, only 12% of the 
elderly population in the United States performs strength training twice a week?2 
Exercise regimens are difficult to implement at a population level and some 
clinicians are reluctant to prescribe high intensity exercise in elderly patients. 23 
Therefore, there is growing interest in developing pharmacological approaches 
that increase muscle mass, strength and physical function. Among the several 
categories of function promoting anabolic therapies in development, myostatin 
antagonists are a leading category. 
In our study we sought to determine the effects of genetic disruption of 
mostatin on age-related changes in muscle mass, muscle strength, aerobic 
endurance, and ambulatory motion. 
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Myostatin. 
One potential therapeutic option to increase muscle mass in development 
is the myostatin inhibitor. Myostatin has been shown to be a potent negative 
regulator of skeletal muscle development, as shown by the seminal paper of 
McPherron and Lee.24 This group reported the extraordinary double muscling of 
the myostatin null (mstn-/-) mouse due to both hypertrophy and hyperplasia of 
the muscle fibers.24 Adult skeletal muscle, heart and adipose tissue all have been 
found to express myostatin.25 
The myostatin gene is composed of 3 exons. The first two exons encode 
the myostatin propeptide and the third exon, the active form of myostatin. 24·26-29 
The myostatin precursor protein must undergo two proteolytic processing events 
in order to generate the biologically active C-terminal fragment. 24·29·30 
As a member of the transforming growth factor-p (TGF-p) superfamily, 
myostatin transduces its signal through type I and type II receptor 
serine/threonine kinases. In particular, active myostatin binds to the activin type II 
receptors, ActRIIA and ActRIIB. 30•31 Myostatin binding to ActRIIB induces the 
recruitment and the phosphorylation of an activin type I receptor that 
phosphorylates and activates the Smad2 and Smad3 intracellular signaling 
proteins. After binding to the common mediator Smad4, the Smad 2/3/4 complex 
translocates to the nucleus to regulate target gene expression .(Figure 2). 
Other than through the Smad pathway, myostatin signals also through the 
mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 
6 
(Erk), and c-Jun amino-terminal kinase (JNK) signaling pathways (Figure 2). 32-35 
For example, myostatin activates the TAK1-MKK6 cascade and the p38 MAPK to 
inhibit myoblast proliferation or the Ras/Erk 1/2 signaling pathway to inhibit 
myoblast proliferation and differentiation. 33·35 Myostatin also inhibits the growth 
and differentiation of muscle cells mediated through the activation of the JNK 
signaling pathway.32 
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Figure 2. Myostatin signaling pathways. Active myostatin dimer binds to ActRIIB 
which recruits and activates by transphosphorylation ActRIB. Next, receptor 
regulated Smad2 and Smad3 are activated which form a complex with Smad4, and 
translocates to nucleus to activate target gene expression. Myostatin has also been 
reported to participate in activation of the MAPK pathways including the p38 
pathway, Erk 1/2 pathway and JNK pathway. 
8 
The myostatin growth factor domain, like many TGF-~ superfamily 
members is highly conserved across species like the humans, pigs, mice, rats, 
chickens and turkeys. 24·36 Thus, it is not surprising the mutation of myostatin 
results in an increase in muscle mass found not only in the mstn-/- mice but also 
cattle, dogs and even humans. In cattle, six different mutations of myostatin 
account for the majority of the breeds of cattle exhibiting the 'double muscling' 
phenotype.37 In 2004, Schuelke and colleagues published a report detailing a 
human child who carried mutations in both copies of the myostatin gene and 
demonstrated pronounced muscle bulk and strength. 38 
Myostatin is expressed prenatally in the developing myotome as well as 
postnatally in adult skeletal muscle. 24·36 While the homozygous deletion of 
myostatin appears to about double the skeletal muscle mass, its heterozygous 
deletion leads to a 25% increase in skeletal muscle mass.36•39 In addition to the 
increased muscle mass, the mice null for myostatin and the cattle carrying 
mutant alleles of myostatin also show reduced fat pad mass and the mice are 
less susceptible to develop obesity and insulin resistance.40-44 Interestingly, 
myostatin deletion during the embryonic and the fetal period of muscle 
development leads to both muscle hyperplasia and hypertrophy whereas the 
inactivation of myostatin during the postnatal period results in only muscle fiber 
hypertrophy. 24,45-48 
The skeletal muscle null for myostatin shows increased percentage of type 
lib fibers, decreased percentage of type lla and type I fibers and more fast 
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glycolytic fibers. 49·50 According with these data on fiber typing , the mstn-/- muscle 
have an overall decreased number of mitochondria and oxidative capacity. 50 
Interestingly, exercise training reverts these proportions seen in the mstn-/- mice, 
with an increase in type I Ia fibers and decrease in percentage of type lib fibers as 
expected by the ability of physical exercise to increase oxidative metabolism. 51 -56 
Myostatin null skeletal muscle have increased myofiber cross sectional 
area, but no parallel increments in muscle force.50·57 On the contrary, the skeletal 
muscle of the mstn-/- muscle shows reduced specific force generation 
suggesting there is no strength advantage for the myostatin-null mice over the 
wild type. 50 Surprisingly, the pharmacological blockage of myostatin in animal 
models of aging and muscular dystrophy results in an overall functional increase 
in strength and specific force generation. 45·58-60 
Myostatin inhibitors. A number of proteins have been demonstrated to 
block myostatin activity, such as the myostatin propeptide, follistatin , follistatin 
related gene (FLRG) and growth and ·differentiation factor-associated serum 
protein-1 (GASP-1) . 30·61 -63 For example, the propeptide blocks the binding of the 
active C-terminal of myostatin with the ActRIIB and ActRIIA receptors.30 In this 
regard, the treatment of mice with a synthetic myostatin propeptide that is 
resistant to cleavage, as well as transgenic mice over-expressing the myostatin 
propeptide, resulted in increased muscle mass and suppressed fat 
accumulation.41·64 
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Follistatin has a high affinity with myostatin and studies suggest may act 
locally on myostatin.65-67 Overexpression of follistatin in transgenic mice results in 
dramatic increase in muscle mass, but is associated with infertility.30,68 
Similar to the above described phenotypes of myostatin blockage in vivo, the 
over-expression of the dominant negative, kinase-dead, form of the ActRIIB, 
resulted in both muscle hyperplasia and hypertrophy associated with 
infertility.30'68 Investigators have also utilized anti-myostatin antibodies to block 
myostatin function, and found increased muscle mass due to hypertrophy and 
increased grip strength.47 
Clinical studies showed limited efficacy of the pharmacological blockade of 
myostatin. A recent clinical trial performed using a "decoy receptor" for myostatin, 
ACE-031, was suspended due to adverse side effects 
(http://www.acceleronpharma.com/products/ace-031/). Whereas, the therapeutic 
treatment with specific anti-myostatin antibodies resulted in minimal improvement 
in the muscle physiology of patients with various forms of muscular dystrophy.69 
Aging and myostatin. It is well established that muscle undergoes 
atrophy with aging. While a study showed that the skeletal muscle of old mstn-/-
mice maintains the muscle hypertrophy observed at the younger age, another 
report suggested that the myofiber hypertrophy in mstn null mice is not sustained 
during aging, but that instead there is the atrophy of the fast glycolytic type lib 
myofibers.70'71 
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Muscle aging is also associated with the shift from glycolytic to oxidative 
fiber profile, characterized by the loss of fast twitch glycolytic fibers and an 
increase in type lla fibers.70·72-74 As shown before, in mstn-/- mice there is an 
increase in type lib fibers and suggested decrease in type I fiber proportionally. 
With aging , mstn-/- mice are less susceptible to increase the percentage of type 
lla fibers when compared to aging wild type mice.70 In general, the mstn-/- mice 
have increased glycolytic type lib myofibers that undergo hypertrophy and are 
maintained in aged muscle. 70·71 Aging does not change muscle fiber number, 
although there are some studies that show that loss of fibers may occur. 73·75-77 
Whereas studies in aging mstn-/- mice reported no change in myofiber 
number.70·71 
The satellite cells are the muscle stem cell population responsible for the 
growth and the regeneration of the skeletal muscle. Studies have reported either 
a decline or no change with aging. 78-81 Myostatin has been shown to modulate 
mouse skeletal muscle mass by inhibiting satellite cell activation and 
proliferation. 82 Accordingly, young myostatin null mice show increased satellite 
cell content, a phenotype that is maintained with aging. 70 
Muscle degeneration, physical performance and myostatin. Mstn-/-
mice are characterized by the accumulation of tubular aggregates and intra-
cytoplasmic inclusions in type lib fibers, a pathological sign of muscle 
degeneration.50·57 This particular aspect shown by the homozygous myostatin 
knockout mice opened the question whether the heterozygous deletion of 
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myostatin may avoid muscle degeneration but still induce increments in muscle 
mass. In addition, the fact that mstn-/- mice demonstrated decreased muscle 
specific force generation despite the strong increment in muscle mass 
highlighted the importance to compare the physical performance between mstn-/-
and myostatin heterozygous experimental models. In this regard, even if in 
general more muscle mass does not mean better physical performance, as 
shown by the "bully" whippet dogs, it is relevant that dogs with only one 
functional myostatin allele perform better than wild type controls. 37·83 This 
evidence prompted me to investigate if and how the loss of both the myostatin 
alleles affect mouse physical performance. 
13 
Articular Cartilage & Fibrocartilage 
Articular Cartilage. Adult articular cartilage is composed of chondrocytes 
embedded within an extracellular matrix (ECM) that consists of two main 
components, collagens and proteoglycans. This unique connective tissue 
undergoes tremendous intensive and repetitive mechanical stress upon physical 
activity, yet is devoid of blood vessels, nerves, and lymphatics. Although articular 
cartilage is subjected to this harsh biomechanical environment, it has a strikingly 
limited ability to heal, an aspect recognized as early as 1743 by the surgical team 
of the Hunter brothers who reported that, "Ulcerated cartilage is a troublesome 
thing .. . once destroyed it is not repaired" . 84 
Tidemark 
Fox et al. 2009 
Modified from Buckwalter et al. 1994 
Used with Permission Sage Publications 
Figure 3. Articular Cartilage Zones. Schematic on the left illustrates the three 
zones of articular cartilage and the differences in chondrocyte shape and 
organization. The outermost region is the superficial tangential zone (STZ), the 
next zone is the middle transitional zone, and the third zone is the deep zone. 
The schematic on the right illustrates the collagen fiber architecture in each of 
these zones. 
14 
The organization of the cartilage is composed of a highly ordered non-
homogeneous structure. The articular cartilage structure is organized into three 
different zones (Figure 3). 85•86 The outermost region exposed to the joint space 
is called the superficial tangential zone (STZ) and is composed primarily of 
collagens that are arranged parallel to the articular surface. 87 This layer has a 
high collagen and low proteoglycan concentration when compared to the other 
zones. 88 The zone functions to support sheer, tensile and compressive forces. 
There are a high number of flattened discoid chondrocytes in the STZ zone. The 
next zone deep to the STZ is the middle transitional zone. 87 In the middle zone, 
the proteoglycans and thicker collagen fibrils are arranged obliquely. 89 There is 
also a higher proteoglycan concentration and lower collagen concentration 
compared to that of the STZ. 87 The chondrocytes in the middle zone are more 
spherical. 87 This zone functions also to resist compressive forces. 89 The third 
zone, the deep zone has a perpendicular arrangement of collagen fibrils and 
chondrocytes in a columnar orientation. The tidemark delineates the deep zone 
of uncalcified cartilage from the calcified cartilage. 
There is only one type of cell within the articular cartilage, the 
chondrocyte. Different cartilage zones have different sized and shaped 
chondrocytes as previously described. Since these cells are embedded in an 
ECM, there is no cell-to-cell contact. Without this contact, the isolated 
chondrocytes are able to respond to a number of stimuli, including growth 
factors, mechanical loads, and are influenced by the composition of the 
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surrounding matrix. 85·90·91 In response to these stimuli , the chondrocytes maintain 
the ECM through synthesis and breakdown of the matrix. 
The ECM is composed of two major elements, collagen and 
proteoglycans. In human articular cartilage, type II collagen comprises 90-95% of 
the collagen in the matrix. 89 Type II collagen, type IX and type XI collagen form 
cross-banded fibril as shown by electron microscopy.87·92 Type IX and XI 
collagen are suggested to stabilize the collagen fibril structure and to provide 
stiffness and strength for the articular cartilage.87 Anther form of collagen, type 
VI , surrounds the chondrocyte and allows the cell to attach to the matrix.93•94 
Similarly, type X collagen surrounds the hypertrophic chondrocytes in the 
calcified zone of cartilage. 87'95-97 Type X collagen is also a component of mouse 
articular cartilage throughout development, growth and aging. 98 
Proteoglycans are made up of a protein core whose amino-acid residues 
are bound to glycosaminoglycan (GAG) chains. 87 The GAGs are negatively 
charged by the presence of polymerized disaccharides that bind positively 
charged ions; for this feature, GAGs draw water into cartilage through an osmotic 
gradient.87·99 The osmotic pressure leads the cartilage to swell and allows the 
articular cartilage to bear load.100'101 There are two major classes of 
proteoglycans: monomers of large aggregating proteoglycans or small 
proteoglycans. Aggrecans constitute the first class of proteoglycans and are 
made up of protein core whose amino acids are linked to chains of chondroitin-
sulfate and keratan-sulfate. 87 Aggrecans also link non-covalently to hyaluronan to 
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form large proteoglycan aggregates.89 Aggrecans fill the interfibrillar space and 
make up 90 percent of the total proteoglycan mass in cartilage matrix.87 The 
second class of proteoglycans includes decorin, big Iycan, and fibromodulin. 102· 103 
Biglycan is found adjacent to the chondrocytes and may interact with collagen 
type VI. 103 Decorin and fibromodulin interact with type II collagen and play a role 
in fibrillogenesis and stabilizing the collagen fibril structure. 103-106 
Articular cartilage is mostly water, up to 80% of the articular cartilage wet 
weight. 85 Dissolved in the water are inorganic ions sodium, calcium, chloride, and 
potassium. 89 The tissue fluid and matrix interaction influences the mechanical 
properties of the tissue. 107· 108 
Endochondral ossification. Endochondral ossification is the process 
responsible for most of the longitudinal bone growth. During development, the 
mesenchyme condenses and the mesenchymal - cells differentiate into 
chondrocytes. In this stage, the mesenchymal cells produce the ECM specific to 
cartilage, type II collagen and aggrecan. To lengthen the bone, the chondrocytes 
proliferate and produce the cartilage matrix; however, the chondrocytes closest 
to the center of the bone (e.g. near the mid-diaphysis of the long bones) stop 
proliferation, increase in size (hypertrophic chondrocyte), and secrete ECM 
components. At this stage, decreased expression of type II collagen, and an 
increased expression of type X collagen are evident. Following differentiation to 
the hypertrophic chondrocytes, the ECM surrounding these cells becomes 
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mineralized. Blood vessel invasion follows and the osteoblasts move into the 
cartilage space and replace cartilage matrix with bone matrix. 109•110 
Endochondral ossification is regulated mainly by two chondrocyte 
signaling pathways, one stimulated by the parathyroid hormone-related protein 
(PTHrP) and another by the Indian hedgehog (lhh) protein. In this regard, PTHrP 
binding to its receptor on the surface of chondrocytes inhibits endochondral 
ossification by delaying chondrocyte differentiation and by promoting 
chondrocyte proliferation. 110• 111 More complex appears the activity of lhh, which is 
expressed by chondrocytes at the stage of pre-hypertrophic-hypertrophic 
chondrocyte, and affects three steps of the chondrocytes differentiation. In the 
first step lhh activates PTHrP to act as described above. In the second step, lhh 
promotes chondrocyte proliferation that leads to the formation of the 
characteristic columns of chondrocytes shown inside the cartilage. In the third 
step, lhh induces osteoblast differentiation from the periosteum.112 
Aging and chondrocytes. Aging results in changes of structure, matrix 
composition, and mechanical properties of the articular cartilage. 113-116 For 
example, articular cartilage thinning and surface fibrillation of the knee joint has 
been reported .117•118 However, this fibrillation of the cartilage does not result in 
joint pain or dysfunction and does not always lead to degeneration of the articular 
cartilage. 119 Aging also induces changes in the structure of the aggrecans of the 
matrix that results, for example, in the reduced size of the proteoglycan 
aggregate, and in the destabilization off the binding between hyaluronan and 
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aggrecans. 115·120-124 As a consequence, the articular cartilage is less hydrated 
and less active to withstand mechanical stress and loads.115· 125-128 For this 
reason, aging changes the mechanical properties of the articular cartilage and 
specifically decreases tensile stiffness and strength. 113 
Chondrocyte function also changes with age. Specifically, chondrocytes 
decrease in mitotic and synthetic activity with aging, and become less responsive 
to the insulin-like growth factor I (IGF-1), an anabolic factor. 129-131 Overall these 
changes with aging do not directly cause osteoarthritis but do increase the risk of 
articular cartilage degeneration. 132 
TGF-{J and BMP related SMAD signaling in chondrocytes. TGF-~ 
family members and bone morphogenetic proteins (BMPs) signaling play integral 
roles in the differentiation of chondrocytes from stem cells to terminal 
differentiation (Figure 4). While TGF-~ and myostatin signal through the receptor-
activated Smad proteins, Smad2 and Smad3, the BMPs signal through the 
receptor-activated Smad 1/5/8 proteins. After the phosphorylation of either Smad 
2/3 and Smad 1/5/8, the respective receptor-activated Smad complex with the 
common mediator Smad 4, and translocate into the nucleus to regulate target 
gene expression. 133-135 
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Figure 4. TGF-13 and BMP related Smad Signaling in chondrocytes. TGF-~ and myostatin signal 
through the receptor activated Smad 2/3 proteins. BMPs signal through the receptor-activated Smad 
1/5/8 proteins. 
Studies have demonstrated that both the TGF-~ and BMP signaling are 
important for early chondrogenesis (Figure 5).136·137 Smad2/3 is crucial in the 
process of cartilage repair and also blocks the terminal differentiation of 
chondrocytes to their hypertrophic stage.137· 138 The phosphorylation of Smad2/3 
is associated with collagen II expression. 139 Whereas, Smad 1/5 have been 
suggested to have a central role not only in the early steps of chondrogenesis, 
but also in the terminal differentiation of chondrocytes.136· 140· 141 
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Figure 5. Smad Signaling During Chondrogenic Differentiation. Illustration of probable 
timing of Smad 2/3 and Smad 1/5/8 signaling during chondrogenic differentiation of bone 
marrow derived mesenchymal stem cells relative to the expression of known differentiation 
markers. 
Myostatin and cartilage. The Gerstenfeld laboratory demonstrated 
multiple members of the TGF-beta superfamily act in combination with a specific 
temporal pattern during intramembranous and endochondral bone formation 
during fracture healing. 142· 143 Notably, myostatin is expressed during the first day 
of fracture healing and regulates the proliferation and possibly the survival of 
osteo- and chondroprogenitor cells.142' 144 Sox-5 is a transcription factor that 
enhances chondrocyte proliferation and delays chondrocyte maturation and · 
hypertrophy; its expression is up-regulated in the fracture callus.145· 146 
Interestingly, the absence of myostatin in mice leads to increased Sox-5 
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expression, callus size, and callus bone volume following an experimental bone 
fracture. 145 In addition, myostatin inhibits the proliferation of bone marrow stromal 
cells and epiphyseal growth plate chondrocytes as well as the chondrogenic 
differentiation, by suppressing Sox-9 expression in bone marrow stromal cells in 
vitro .147 These data appear to indicate that myostatin inhibits both chondrocyte 
proliferation and differentiation. 
Menisci Fibrocartilage. The human knee joint menisci are located 
between the femoral condyles and the tibial plateau. The peripheral rim of the 
menisci attaches to the joint capsule. The menisci also have insertions into the 
tibia, and these entheses are attached to the anterior and posterior insertional 
ligaments. The shape and insertional anatomy of the knee joint menisci are found 
in all mammals but vary in certain species. 148 The key difference between the 
human and rat menisci are that the rat develops central ossicles. 148 In addition, it 
is important to note that there are major differences in how the limb is used by 
different mammals and thus can limit the use of animal models. 148 
In the human meniscus there are two cell ·populations based on the 
location on the meniscus.149 The fibrocartilage of the inner and the middle part of 
the meniscus contains round or oval cells, described as fibrochondrocytes.150 
These cells are comparable to fibroblasts and chondrocytes of the articular 
cartilage.149 The distinguishing feature of the menisci fibrochondrocyte is that it 
produces type I collagen as opposed to the type II collagen produced from 
articular chondrocytes. 15° Fibroblast-like cells with dense connective tissue 
22 
populate the outer portion of the meniscus that also contains vascular and 
nervous tissue. 149 The ECM of the meniscus is composed mostly of two major 
components: glycosaminoglycans (GAGs) and collagen.149·150 Little is known 
about the distinct cell populations of the mouse meniscus. 
When comparing the composition of the meniscus in different species, we 
can identify two main morphological features: dense bundles of collagen, as 
shown in the meniscus of man, monkey, dog, cat and rabbit, and a distinct 
change between the inner and the outer meniscus margin, as shown in guinea-
pig and rat. 151 The major difference between the first group of species and the 
guinea-pig and rat are the areas of ossification normally embedded within the 
meniscus. 151 These areas of ossification have been referred to as 'ossicles' or 
lunulae' in the hamster, mouse, guinea-pig and rat. 
The concentration of proteoglycans and collagen is higher in the posterior 
region of the rat meniscus, suggesting that this regional difference in distribution 
might be related to unique biomechanical properties.152 In addition, the presence 
of ossicles in the anterior region may support the anatomical or mechanical 
"congruity" between the tibia and the femur. 153 In support of this hypothesized 
relationship between the anatomy of the meniscus and the mechanical activity of 
the hindlimb, there is the observation that during the step cycle of the rat, the 
hindlimb remains mostly in the flexed position, suggesting that the posterior 
meniscus region may have greater load-bearing forces.154 In addition, Vailas et 
al. found in the rat that the posterior horn of the lateral meniscus thickened 
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slightly and increased significantly in calcium, hydroxyproline and uronic acid 
level during exercise.155 These studies suggest the changes in load demand on 
the meniscus can lead to adaptations that may increase the calcification in 
certain regions. 
The meniscus functions in load bearing, load transmission , shock 
absorption, joint stability, joint lubrication and joint congruity. 156-159 The two major 
components of the ECM function in two different ways, the GAGs provide 
compressive strength whereas the collagen provides tensile strength.160·161 
Normally the load in the joint is distributed with an intact meniscus and the load 
on the joint structure may influence the thickness of calcified tissue under the 
enthesis or articular cartilage surface. 162•163 When the menisci are removed the 
peak stresses on the tibial cartilage are increased.164-167 Figure 6 from Messner 
and Goa depicts the joint load distribution.148 
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Figure 6. Menisci Load Transmission. Schematic illustrates importance 
of intact meniscal entheses for load distribution. The top two figures show 
how the load (thick arrows) is transmitted through a large contact area 
(small arrows on top left) and laterally through the mensicus (top right) (a). 
After transection of the meniscus insertional ligaments (bottom right) , 
during loading the meniscus will extrude from the knee and the load is 
transmitted to a reduced contact area (bottom left) (b) . 
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Mineralization 
The main mineral formed inside the ECM is a type of calcium phosphate 
called hydroxyapatite. The apposition of mineral can be classified as 
physiological and pathological mineralization. Physiological mineralization 
occurs, for example, in bone, with hypertrophic chondrocytes and dentin whereas 
the pathological mineralization can occur in the articular cartilage in particular 
conditions. 168·169 Defective mineralization has been associated with aging . 170-173 
In cartilage calcification, the calcium and phosphorus for mineralization is 
provided in mammals by the blood circulation. The calcium is deposited in the 
extracellular matrix where the negatively charged proteoglycans of the ECM may 
bind calcium. Phosphorus concentrations must also be maintained in a 
physiological normal range in order to achieve an adequate calcium X phosphate 
product to produce the mineral, hydroxyapatite.174·175 Both calcium and 
phosphate are supplied to regions of mineralization by the blood circulation .176 
There are endocrine mechanisms that regulate both calcium and phosphate. 
Calcium is regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin 
D, the active form of vitamin D. PTH is produced from the parathyroid gland in 
response to a decrease in the blood-ionized calcium concentration. In the kidney, 
PTH increases the renal tubular reabsorption of calcium and the renal clearance 
of phosphorus. PTH also enhances the production of 1,25-dihydroxyvitamin D3 in 
the kidney.177 As a review, through exposure to solar ultraviolent B radiation, 7-
dehydrocholesterol is converted to previtamin D which in turn is rapidly converted 
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to vitamin Din the skin. 178•179 Vitamin D can also be derived from dietary 
sources, an example being diets high in oily fish. 179 Furthermore, vitamin D is 
metabolized by 25-hydroxylation in the liver to 25-hydroxyvitamin D, this 
intermediary product is metabolized by 1 a-hydroxylation in the kidney which 
results in the biologically active form 1 ,25-dihydroxyvitamin 0 3 .177· 180 PTH and 
1 ,25-dihydroxyvitamin 03 regulate the calcium and phosphorus in two target 
organs: (1) the small intestine and (2) bone. In the small intestine, the direct 
effect of the interaction of 1 ,25-dihydroxyvitamin D with the vitamin D receptor 
increases calcium absorption. 179 PTH binds to the PTH receptor in the kidney 
stimulating the renal 1 a-hydroxylase activity that increases the conversion from 
25-hydroxyvitamin D to the active form of vitamin D. 181 In bone, 1,25-
dihydroxyvitamin D also targets its receptor in osteoblasts which increases 
receptor activator of nuclear factor-KB ligand (RANKL) expression. The receptor 
on preosteoclasts, RANK, binds RANKL promoting the maturation to osteoclasts 
which mobilizes calcium from the bone. 179·180·182 Raised serum-ionized calcium 
concentrations result in a negative feedback that regulates the synthesis and 
secretion of PTH. It is important to note that without the active form of vitamin D, 
mineralization still occurs. 183-185 The principal function of vitamin D is to maintain 
an adequate supply of calcium and phosphorus to enable the mechanism of 
mineralization to occur. 
The initial evidence of a morphological relationship between specific bone 
structures and mineralization has been reported in studies that correlated 
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mineralization with the matrix vesicles (MVs). 186·187 The MVs bud from the cellular 
membrane of hypertrophic chondrocytes. 168·188-19° Compared to the parent 
cellular membrane, MV membranes are characterized by a high level of tissue 
nonspecific alkaline phosphatase and phosphatidylserine. 191 -196 
During the process of mineralization, both hypertrophic chondrocytes and 
osteoblasts secrete an organic matrix composed of type II or type I collagen, 
respectively.197 These cell types also regulate the concentration of various ions 
present in the extracellular space, by using Ca2+ and P043- ion pumps located on 
their cellular membrane. 198'199 
While the Ca2+ stored in the ECM is supplied by the blood, the intracellular 
P043- of chondrocytes and osteoblasts is provided by the blood or is produced by 
the hydrolysis of the adenosine triphosphate (A TP), to generates inorganic 
pyrophosphate (PPi), and by the hydrolysis of adenosine monophosphate (AMP), 
to generates the inorganic phosphate (Pi). 197·20° Critical levels of both Ca2+ and 
inorganic phosphates are necessary to form the hydroxyapatite that accumulates 
within the matrix. 201 MVs play a crucial role in this process, because they 
regulate the appropriate ratio between PPi and Pi concentrations. 197 For 
example, MVs help to maintain ECM PPi at low concentrations, which act as 
potent inhibitors of mineral formation. 197 
Some major proteins affect PPi concentration in the extracellular matrix: 
the progressive ankylosis protein (ANK), the nucleotide pyrophosphatase 
phosphodiesterase (NPP1 ), and the tissue nonspecific alkaline phosphatase 
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triphosphates to release extracellular PPi, TNAP facilitates the conversion of PPi 
to Pi , reducing the amount of PPi in the ECM space.209 During the process of 
mineralization, TNAP is upregulated and 1,25-dihydroxyvitamin D, stabilizes 
TNAP mRNA to increase TNAP protein content. 210-212 The MVs contain both 
NPP1 and TNAP, a point that may explain their crucial role in regulating the PPi 
to Pi ratio. 205-209 
When mineralization occurs, hydroxyapatite fills the collagen fibrils and 
matrix areas around MVs and cells. 197 The model of mineral nucleation defines 
the mineralization in two steps (Figure 7) .168·209 The first step is the formation of 
hydroxyapatite crystals in the MVs. The second step is the release of 
hydroxyapatite from MVs to the ECM with the concurrent import of Ca2+ and 
inorganic phosphate ions into the MVs.213-215 Once within the MV these ions form 
a "nucleational core complex" with phospholipids to form nanocrystals. 216-219 
Nanocrystals in turn exit the MVs by unknown mechanisms. 220-223 The direct 
nucleation model proposes that mineral nucleation occurs not in the MVs but 
directly in the extracellular matrix. 224-228 
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Figure 7. Illustration of the process of mineralization. First, matrix vesicles bud off from 
hypertrophic chondrocytes and osteoblasts. Next, hydroxyapatite is formed from Ca2+ 
transported in by the annexin calciu~ channel and from inorganic phosphate (Pi) transported 
from the type Ill Na/Pi cotransporter. Pi also is provided by the PHOSPH01 which hydrolyzes 
phosphocholine (PCho) and phosphoethanolamine (PEA) from the matrix vesicle membrane. 
Inorganic pyrophosphate (PPi) inhibits hydroxyapatite formation and is formed by nucleotide 
pyrophosphatase phosphodiesterase 1 (NPP1) and provided by the hypertrophic chondrocytes 
and osteoblasts through ANKH. Tissue nonspecific alkaline phosphatase (TNAP) hydrolyzes 
PPi to Pi . 
MVs also play a role in pathological mineralization. 197•229 For example, 
ultrastructural analysis of arthritic cartilage has identified MV-Iike particles but 
many questions remain to elucidate the mechanism of pathological 
mineralization . 21 4·229·230 
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II. Hypothesis & Specific Aims: 
Musculoskeletal disorders are the most common causes of long-term pain 
and physical disabilities affecting hundreds of millions of people around the 
world. Aging is associated with muscle loss and physical disability. In addition, 
aging is a risk factor for the loss of cartilage due to osteoarthritis, another 
disorder that compromises physical activity. 
Myostatin belongs to the TGF-~ superfamily and is known as a negative 
regulator of muscle growth. Hypermuscularity in myostatin knockout mice has 
been widely recognized and numerous myostatin inhibitors are in development to 
treat sarcopenia associated with aging and chronic illnesses. Although it is clear 
that the inhibition of myostatin increases muscle mass in a dose-dependent 
manner, it is still unknown how the long term blockade of myostatin affects 
overall physical performance. 
Moreover, myostatin may also play a role in the differentiation of 
chondrocytes and in cartilage maintenance. Articular cartilage is subjected to a 
harsh biomechanical environment, yet this tissue demonstrates strikingly 
ineffective self-repair. In this regard, it still unclear if the long-term loss of 
myostatin affects the maintenance of the joint articular cartilage and fibrocartilage 
in vivo. 
My preliminary data suggested that myostatin regulates the maintenance 
of articular chondrocytes throughout the aging process and allowed me to identify 
the experimental goals of this study. 
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• To determine whether chronic myostatin deficiency in vivo 
affects physical performance. 
• To investigate the effect of long-term myostatin deficiency on 
joint morphology. 
I have designed the experiments according with the following aims: 
Aim 1: Examine the effect of age-related myostatin deficiency on physical 
performance. 
Rationale: Since myostatin is a negative regulator of muscle mass, it would be 
therapeutically relevant to develop a myostatin inhibitor to treat sarcopenia and 
other diseases that lead to muscle wasting and degeneration. Limited work has 
been performed investigating the long-term effects of myostatin loss on physical 
performance. In this aim I will test the hypothesis that as the mice progress to old 
age the absence of myostatin improves physical performance compared to wild 
type. 
Aim 2. Examine the effect of age-related myostatin deficiency on joint 
morphology. 
Rationale: It is still unknown if the long-term loss of myostatin induces adverse 
effects, for example, associated with the articular cartilage in vivo. In this aim I 
will test the hypothesis that the loss of myostatin will lead to proliferation and 
terminal differentiation of the chondrocytes. 
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Ill. Materials and Methods: 
Mice. Myostatin null mice in Balb/c background were provided by Dr. Se-
Jin Lee (Johns Hopkins University). Myostatin null mice were backcrossed to 
C57BL/6 for :a:: 10 generations. Age-matched control mice were purchased from 
The Jackson Laboratory. All animals were handled and approved in accordance 
with the guidelines of the Institutional Animal Care and Use Committee at Boston 
University School of Medicine. Animals were euthanized under isoflurane in a 
closed receptacle and were never in direct contact with isoflurane, death of 
mouse was confirmed with cervical dislocation with the cross-sectional groups of 
animals at 5-6 months, 15-16 months and 22-23 months of age (n=6-12). 
Body Composition. Muscle mass and whole body fat was measured by 
nuclear magnetic resonance (NMR; EchoMRI-700, Echo Medical System) for 
each cross-sectional age group. The overall mass of the mouse was measured 
and the left limbs were extracted and muscle mass of the tibialis anterior, 
gastrocnemius, bicep, and levator ani were similarly measured (n=6-12) . 
Physical Performance Measures 
Treadmill Endurance. Measurements were performed using the Exer 3/6 
Animals Treadmill (Columbus Instruments). Acclimated mice (n = 9-10 per 
group) were allowed to run on the treadmill at a speed of 10 m/min and grade of 
5% for 4 minutes. Every subsequent 4 minutes, the speed was increased by 2 
m/min until the mice were unable to remain on the treadmill despite an electrical 
shock stimulus. 
33 
Grip Strength. Forearm grip strength was measured by computerized grip 
strength meter (Columbus Instruments). Seven measurements of total peak force 
(in N) were recorded from each animal. The average of the seven values was 
used for statistical analysis. 
Activity Monitoring. Ambulatory motion was measured by placing mice in 
the OxyMax 4.20 metabolic cage system (Columbus Instruments). Animal 
movements in the x, y and z axes inside the cage were monitored by infrared 
sensor. Animals were acclimated to the chamber for at least 8 hours. Data shown 
are taken during the period of greatest activity from a successive 12-hour period 
from ?pm to ?am the next day. 
Imaging & Histology 
Flat Film. Dissected hind limbs were analyzed by X-ray with a MX-20 
Specimen Radiography System (Faxitron X-ray Corporation) . Specimen were 
scanned for 90 s at 30 kV using Hyblot CL films (Denville Scientific Inc). 
Radiographs of the mouse knee joints were taken in the mediolateral projection. 
Ossification in the knee joint space was quantified using lmageJ software (NIH, 
Bethesda, MD). The freehand selection function was utilized to trace the 
ossification of the meniscus, calcification in the joint space surrounding the 
meniscus, and patellar ligament yet excluding the sesamoid bones and patella. 
MicroCT. After euthanasia, the forelimb was dissected from the shoulder 
and hindlimb from the hip. Tissue samples were fixed in 4% paraformaldehyde 
for 7 days and transferred to PBS. 3-dimensional micro-CT was utilized to 
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examine changes in knee and ankle structure. The limbs were affixed to a 
cylinder with foam. Cylinder was placed in micro-CT machine (microCT40; 
Scanco Medical) Area around the joints were scanned using following standard 
operation protocol. Joint space calcification was determined in a region defined 
by the first transverse slice distal to the patella and ended at the first slice above 
or below where the tibial growth plate was evident. All joint space calcification 
was outlined using contouring and bone volume in these traced regions were 
measured. 
Histology. Dissected hind limb was fixed in 4% paraformaldehyde, 
decalcified with 14% EDTA and embedded in paraffin. Serial sections were 
prepared and stained with hematoxylin and eosin. 
Statistical analysis 
Graphpad Prism (Graphpad Prism Software) was used to perform 
statistical analyses using two-way ANOVA, the Sidak and Tukey HSD post hoc 
test of the means (n=6-14 samples per group). Statistical analysis of the 
ambulatory motion was performed on SAS (SAS Software, Cary, NC) using 
AN OVA and the Tukey HSD post hoc test of the means (n=8 samples per group). 
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IV. Results: 
Ankle Morphology 
A 
wt (II month) mstn-1· (I I month) 
B 
wt (II month) mstn·/- (I I month) mstn-/- (3 month) 
c 
Figure 8. Ankle Morphology. The mstn-/- males exhibited a reduced 
range of plantar flexion of the ankle with curling of toes and swelling of the 
heel (Right) compared to age-matched wild type (Left)(A). The mstn-/-
mice began to exhibit the reduced plantar flexion angle between 9-12 
months of age (Middle), whereas the aged-matched wild type (Left) and 
younger mstn-/- mice (Right) remain unaffected . (B) A significant decrease 
in the ankle peak plantar flexion angle is observed in both left and right 
ankles when comparing the mstn-/- to wild type (WT) at 15-16 and 22-23 
months. With age, the mstn-/- peak plantar flexion angle is significantly 
reduced at 15-16 and 22-23 months compared to 5-6 months. **p<0.01, 
***p<0.001, ****p<0.0001 (C) 
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To determine whether the lack of myostatin has any effect on the peak 
plantar flexion of the ankle, the angle formed between the posterior region of the 
tibia and the plantar surface of the foot in both wild type and mstn-/- mice was 
measured (Figure 8). As the mstn-/- mice age there is a noted loss of passive 
flexion in the ankle joints. At 5-6 months of age, both wild type and mstn-/- mice 
showed the same 180 degrees of peak plantar flexion in both the left and right 
ankle. However, the 15-16 month old mstn-/- mice peak plantar flexion angle was 
significantly reduced to an average of 144.4 degrees and 128.3 in the left and 
right ankles, respectively , when compared with the age-matched wild type mice. 
Similar significant reduction was obtained by comparing the measures of this 
parameter acquired on both ankles of the 22-23 month old mstn-/- and wild type 
mice. 
When comparing the age effects within the mstn-/- mice groups, the peak 
plantar flexion values show at 15-16 months a 20% and 25% reduction from 5-6 
months in the left and right ankle, respectively. No significant difference in ankle 
flexion was measured between 15-16 month and 22-23 month old mstn-/- mice. 
In stark contrast, the wild type mice show no change of peak plantar flexion angle 
with age. 
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Body Mass 
**** 
**** 
Figure 9. Wild Type and Myostatin Null Body Mass. The 
mstn-/- mice body mass are significantly lower at 15-16 and 
22-23 months (mo) of age compared to age-matched wild · 
type (WT) controls. Both the WT and mstn-/- body mass 
increases between 5-6 and 15-16 months.*p<0.05 **p<0.01, 
****p<0.0001 
When comparing the overall mass of the mice at each age group (Figure 
9) , there was no significant difference between the wild type and mstn-/- at 5-6 
months. At 15-16 months 22-23 months, the wild type body mass was 16% and 
17% more than the age-matched mstn-/- mice, respectively. The age effect on 
body mass within each mouse groups was also measured. The mass of wild type 
mice increased significantly an average of 17.5 grams from 5-6 months to 15-16 
months of age. The significant increase in mass of the 22-23 month old wild type 
mice is maintained when compared to the 5-6 month counterparts. The body 
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mass of the mstn-/- mice did not increase with the same magnitude as the wild 
type and only increased less than 6 grams between 5-6 and 15-16 months and 
less than 4 grams between 5-6 and 22-23 months of age. 
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Figure 10. Lean Body Mass. Lean body mass normalized to total body mass: Mstn-/- mice have 
significantly higher lean body mass at 5-6 and 22-23 months (mo) of age compared to age-
matched wild type (WT) controls. WT mice lose lean body mass between 15-16 mo and 22-23 mo 
of age. Non-normalized lean body mass: Mstn-/- mice at 5-6,15-16, and 22-23 mo have 
significantly higher lean mass compared age-matched WT controls . With age, the WT lean muscle 
mass increases significantly from 5-6 to 15-16 and 22-23 months. *p<0.05, **p<0.01 , ****p<0.0001 
To understand the differences in body weight at 15-16 months and 22-23 
months between the mstn-/- and wild type mice, the lean and fat body masses of 
the mice were measured (Figure 10 & 11 ). The normalized wild type lean body 
mass was consistently less than 74% of the total body mass, whereas the mstn-/-
mice were consistently greater than 81% of the total body mass. The measure of 
the non-normalized lean mass confirmed the increased percentage of normalized 
lean body mass shown in the mstn-/- mice. At all three age groups the mstn-/-
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non-normalized lean mass was significantly greater compared to their age-
matched controls . 
The effect of age on lean body mass was also measured. The mstn-/-
normalized and non-nomalized lean body mass exhibited no significant change 
across the three age groups. Whereas, the wild type non-normalized lean body 
mass measurements significantly increased an average of 6.6 grams at 15-16 
and 22-23 months when compared to 5-6 months. 
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Figure 11. Fat Body Mass. Fat body mass normalized to total body mass: Mstn-/- mice have 
significantly lower fat body mass at 5-6 and 22-23 months (mo) of age compared to age-
matched wild type (WT) controls. WT fat body mass increases between 5-6 mo and 15-16 mo 
to 22-23 mo of age. (A) Non-normalized fat body mass: Mstn-/- mice have significantly lower fat 
body at 22-23 mo of age. WT fat body mass increases significantly between 5-6 mo and 15-16 
mo to 22-23 mo. (B) **p<0.01, ***p<0.001 , ****p<0.0001 
To understand the differences in body weight between the mstn-/- and 
wild type mice at 15-16 and 22-23 months of age, the fat mass was also 
assessed. The non-normalized fat mass measurements of the 22-23 month wild 
type mice show a 10 gram difference that is significantly greater than its age-
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matched mstn-/- mice. This significant increase is also reflected in the 21.1% 
difference in the higher normalized wild type fat mass compared to the 
normalized mstn-/- fat mass. 
When comparing across age groups, the mstn-/- mice show no significant 
change in normalized fat body mass, whereas, the wild type mice fat body mass 
increased significantly between 5-6 months and 22-23 months and between 15-
16 months and 22-23 months of age. 
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Figure 12. Gastrocnemius Mass. Gastrocnemius mass normalized to total body mass: 
Mstn-1- mice have significantly higher gastrocnemius (gastroc) mass at all age groups 
compared to age-matched wild type (WT) controls. Mstn-1- and WT mice both have 
significantly reduced gastroc mass between 5-6 and 22-23 months (mo) of age.(A) Non-
normalized gastrocnemius mass: Mstn-1- mice have significantly higher gastroc mass at all 
age groups compared to age-matched WT controls .(B) *p<0.05, ***p<0.001 , ****p<0.0001 
To identify the reason for the increased lean mass of the mstn-/- mice 
compared to the wild type mice during aging, I measured the wet weights of 
individual gastrocnemius, tibialis anterior, levator ani and bicep muscles (Figures 
12-15). Muscle weight as a fraction of total body mass (milligram of muscle/gram 
of total body mass) was also calculated. At each of the three aging timepoints, 
the mstn-/- gastrocnemius mass(Figure 12) was >1.5 fold greater than the age-
matched wild type gastrocnemius muscle (p<0.0001, respectively for each age 
time point) . With age, both the wild type and mstn-/- mice showed a significant 
decrease in normalized gastrocnemius muscles mass between 5-6 and 22-23 
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months when the muscle mass was normalized to total body mass. The 
gastrocnemius wet mass only revealed a 10% decrease in the mstn-/- mice 
between 5-6 and 22-23 months of age (p<0.05) . 
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Similar to the gastrocnemius, the tibialis anterior muscle mass (Figure 13) 
of the mstn-/- mice was also >1.5 fold greater than the wild type mice in each age 
class (p<0.0001 , respectively for each age time point) . When comparing the age 
effect within each mouse group, the tibialis anterior muscle of the wild type mice 
and mstn-/- mice showed at 22-23 months a significant decrease when 
compared to 5-6 months when the muscle mass was normalized to total body 
mass(p<0.0001 , respectively) . The non-normalized tibialis anterior muscle of the 
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mstn-/- mice only showed a 10% decrease between 5-6 months and 22-23 
months of age (p<0.05). 
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Figure 14. Bicep Mass. Bicep mass normalized to total body mass: Mstn-/- mice have 
significantly higher bicep mass at all age groups compared to age-matched wild type (WT) 
controls. Both mstn-/- and WT mice bicep mass significantly decreases between 5-6 and 22-23 
months (mo) of age.(A) Non-normalized bicep mass: Mstn-/- mice have significantly higher 
bicep mass at all age groups compared to age-matched WT controls . (B)**p<0.01, ***p<0.001, 
****p<0.0001 
The mass of the mstn-/- biceps muscle (Figure 14) was significantly larger 
compared to that of wild type mice in all the three age groups which is consistent 
with the gastrocnemius and tibialis anterior comparisons. Both wild type and 
mstn-/- mice showed a significant decrease in normalized bicep mass between 
the 5-6 month and 22-23 month old mice. In contrast to the mstn-/ 
gastrocnemius and tibialis anterior muscle there was no change in mstn-/- non-
normalized bicep muscle mass when comparing the 5-6 month and 22-23 month 
groups. Whereas, the age effect showing a significant decrease in normalized 
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bicep mass in the mstn-/- and wild type mice between the 5-6 month and 22-23 
month groups was consistent with the normalized gastrocnemius and tibialis 
anterior comparisons. 
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Figure 15. Levator Ani Mass. Levator ani mass normalized to total body mass: Mstn-/- mice 
have significantly higher levator ani (LA) mass at all age groups compared to age-matched 
wild type (WT) controls. Mstn-/- mice LA mass significantly increases between 5-6 and 15-16 
months (mo) of age and is maintained at 22-23 mo.(A) Non-normalized levator ani mass: 
Mstn-/- mice have significantly higher LA mass at all age groups. The age effect of the 
mstn-/- mice is similar to the normalized LA measurements. The WT LA increases 
significantly between 5-6 and 15-16 mo ofage.(B) *p<0.05, ***p<0.001, ****p<0.0001 
In addition , the levator ani muscle was measured to assess the age and 
myostatin related effects on muscle mass of a muscle not directly utilized for 
physical performance measured in my study (Figure 15). When comparing the 
levator ani muscle of the mstn-/- and the wild type the pattern is consistent with 
the gastrocnemius, tibialis anterior and bicep and shows the mstn-/- levator ani 
muscle is significantly greater at each increasing age group when compared to 
its age-matched control. When comparing the non-normalized wild type levator 
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ani muscle mass across age groups, a 1.9 fold increase between 5-6 months and 
15-16 months (p<0.0001) and a 0.8 fold decrease was found comparing the 15-
16 and 22-23 month mice (p<0.0001 ). 
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Figure 16. Horizontal Ambulatory Motion. The horizontal ambulatory motion 
(HZAM) includes the ambulatory motion from both X and Y axes. The mstn-/- mice 
show reduced HZAM at 5-6 and 15-16 months of age. The wild type HZAM was 
significantly increased between 5-6 and 15-16 months and significantly decreased 
between15-16 and 22-23 months of age. The mstn-/- HZAM was significantly 
increased between 5-6 and 15-16 months and between 5-6 and 22-23 months of age. 
**p<0.01, ****p<0.0001; A: WT 5-6 vs 15-16 months, p<0.0001, 15-16 vs 22-23 
months, p<0.0001, 5-6 vs 22-23 months, p<0 .05; 8: mstn-/- 5-6 vs 15-16 months, 
p<0.0001 , 5-6 vs 22-23 months, p<0.0001 
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To characterize the effects of age and myostatin on the physical function 
of mstn-/- mice, the ambulatory activity of mstn-/- and wild type mice over the 12-
hour period of the day when the activity of the mouse is maximal was measured. 
Mouse ambulatory activity was analyzed considering two parameters, the 
horizontal motion, that includes measures of the X and Y axes of the space 
(Figure 16), and the vertical motion that represent the movement of the mouse 
along the Z-axis of the space (Figure 17). 
The horizontal ambulatory activity in the horizontal plane of the mstn-/-
mice was significantly reduced at 5-6 and 15-16 month of age when compared to 
age-matched wild type mice. On the contrary, 22-23 month old wild type and 
mstn-/- mice demonstrate no difference in the combined X and Y ambulatory 
measurements. When analyzing the effect of age in both mstn-/- and wild type 
mice, the 15-16 month old mice showed a significant increment in the horizontal 
ambulatory activity when compared to the younger class of age. From 15-16 
months to 22-23 months, the wild type mice showed a significant decrease in 
ambulatory activity. The significant decrease in horizontal ambulatory motion in 
the wild type mice between 15-16 and 22-23 months was not observed in the 
mstn-/- mice. When comparing between 5-6 and 22-23 months, the wild type and 
mstn-/- mice both show a significant increase in horizontal ambulatory motion. 
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Figure 17. Vertical Ambulatory Motion. The vertical ambulatory motion (VTAM) includes 
the ambulatory motion from the Z-axes. The mstn-/- mice show reduced VTAM at each age 
group. Both the wild type and mstn-/- mice exhibit significant increase between 5-6 and 
15-16 months and significant decrease between 15-16 months and 22-23 months in VTAM. 
****p<0.0001 ; A: WT 5-6 vs 15-16 months, p<0.0001, 15-16 vs 22-23 months, p<0.0001, 5-6 
vs 22-23 months, p<0.01 ; 8 : mstn-/- 5-6 vs 15-16 month , p<0.0001, 15-16 vs 22-23 month , 
p<0.05 , 5-6 vs 22-23 months, p<0.0001 
The Z-axis ambulatory activity of the mstn-/- mice was significantly 
reduced when compared to the age-matched wild type control at each age group 
(p<0.0001, respectively for each age time point) . With age in both mstn-/- and 
wild type groups, there is a significant increment between the 5-6 month and 15-
16 month groups and a significant decrement between 15-16 month and 22-23 
month-old mice. 
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Figure 18. Grip Strength. At 5-6 months mstn-/- mice have 
significantly greater grip strength than age matched wild type 
(WT) control. With age, mstn-/- mice have significantly 
reduced grip strength between 5-6 to 15-16 and 22-23 
months of age. *p<0.05 , ****p<0.0001 
To expand the analysis on the physical performance in the presence and 
in the absence of myostatin in the mouse, the grip strength test was performed 
(Figure 18). The 5-6 month old mstn-/- mice showed a 30% greater grip value 
(p<0.0001) when compared to their aged-matched wild type controls; however, 
older mstn-/- mice showed measures of grip strength equal to their aged 
matched controls. 
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When observing the age effect, the wild type mice showed a slight 
decrease between 5-6 months and 22-23 month (p<0.05) . Whereas, the mstn-/-
mice demonstrated a significantly decreased grip strength at 15-16 and 22-23 
months when compared to 5-6 months (p<0.0001, respectively) . 
Treadmill Endurance 
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Figure 19. Endurance Capacity. Mstn-/- mice have significantly lower treadmill run time at 
each age group compared to age-matched control. With age, mstn-/- and wild type (\fliT) 
mice both have reduced treadmill run time at 15-16 and 22-23 months when compared to 
their 5-6 month counterparts. *p<0.05, **p<0.01 , ***p<0.001, ****p<0.0001 
To complete the characterization of the effects of age and the loss of 
myostatin on mouse physical function, I additionally performed the treadmill 
endurance test (Figure 19). At all three age groups, the mstn-/- mice 
demonstrated >25% less run time compared to their age-matched controls. 
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When analyzing the age effect, both the 15-16 month and the 22-23 month old 
mstn-/- and wild type mice showed a significant reduction of the run time when 
compared to their 5-6 month-old corresponding cohorts. 
Knee X-Ray 
Overall, the results demonstrate long term myostatin deletion does not aid 
in the maintenance of overall physical performance as the animal ages. Since 
prior studies had also shown that myostatin affected both bone mass, cartilage 
development and skeletal tissue repair the effects of myostatin deletion were 
next examined relative to skeletal tissue structure and function. 
Wild Type Myostatin-null 
Figure 20. Knee X-Ray. Orange arrows indicate the radio-dense areas measured for 
quantification in the joint space of the 22-23 month old wild type and mstn-/- mice. 
Qualitatively, the mstn-/- mice have larger radio-dense regions in the knee joint space 
(right) compared to the wild type knee joint space (left) . 
First, knee x-ray produced sagittal radiographs showing the junction 
between tibia and femur at the level of the knee (Figure 20) . The measurement of 
joint space ossification included the radio-dense areas representing the anterior 
and posterior meniscus (Figure 21) . The two sesamoid bones were not included 
in the quantification of the calcification of the joint space. The 5-6 month old 
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mstn-/- and wild type mice showed no difference in the joint space calcification. 
However, at the age of 15-16 months, the mstn-/- mice developed a 3.1 fold 
greater radio-dense areas in the anterior and posterior regions of the meniscus 
as well as in the joint space, when compared to the age-matched wild type mice 
(p<0.05). A significant increment of these radio-dense regions inside the joint 
space was found in the oldest mstn-/- mouse class, 2. 7 fold greater when 
compared to their age-matched control (p<0.0001 ). 
When analyzed as single strain , wild type mice showed a trend of 
increased calcification during aging, albeit the difference of the values of 
densitometry did not reach the level of significance. In contrast, the mstn-/- mice 
showed a more significant 4.4 fold increase in joint space radio-density from 5-6 
months to 15-16 months (p<0.01) and a significant 1.6 fold increase from 15-16 
months to 22-23 months of age (p<0.05) . Overall, these data demonstrate that 
the absence of myostatin results in the increased calcification of the knee during 
aging. 
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Figure 21. Knee Joint Space Calcification. 
Significantly increased joint space calcification in 
15-16 and 22-23 month mstn-/- mice measured by X-
ray imaging. With age, the mstn-/- joint space 
calcification increases significantly from 5-6 to 15-16 
to 22-23 months of age. The wild type (WT) joint 
space calcification does not change significantly with 
age. *p<0.05, **p<0.01, ****p<0.0001 
Knee MicroCT 
In order to determine the changes in bone morphology, microCT imaging 
was performed on the knee of the three age groups of mice. 5-6 month old mstn-
/- and wild type mice didn't show qualitative difference in the bone morphology of 
the knee. However, the 15-16 month and the 22-23 month old mstn-/- mice 
demonstrated a highly significant qualitative difference compared to the age-
matched wild type mice. In fact, the anterior, medial, lateral, and posterior views 
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of the mstn-/- meniscus of these two groups of mice was enlarged compared to 
their age-matched wild type mice (Fig 22, 23, 24, 25). 
wild type 
myostatin 
null 
5-6 month 15-16 month 22-23 month 
Figure 22. MicroCT Anterior View of Right Knee. The top row of figures shows the wild type group at the 
three age groups. In the wild type, a slight increase in the wild type meniscus size at 15-16 and 22-23 months 
of age compared the 5-6 month mice. The bottom row shows mstn-/- mice at 15-16 and 22-23 months of age 
have an enlarged meniscus (orange arrows) when compared to 5-6 month counterparts and the age-
matched wild type controls. 
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Figure 23. MicroCT Lateral View of Right Knee. The top row shows the menisci of wild type mice slightly expands in 
size with increasing age. The bottom row shows the mstn-/- mice at 15-16 and 22-23 months of age have menisci with 
enlarged, elongated and flattened shape (orange arrows) when compared with their 5-6 month counterparts and age-
matched wild t e controls. 
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Figure 24. MicroCT Medial View of Right Knee. The top row of figures shows the slight increase in the wild type 
meniscus size at 15-16 and 22-23 months of age compared the 5-6 month mice. The bottom row shows mstn-/- mice 
at 15-16 and 22-23 months of age have an enlarged meniscus (orange arrows) when compared to 5-6 month 
counterparts and the age-matched wild type controls. 
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Figure 25. MicroCT Posterior View of Right Knee. The top row of figures shows the slight increase in the wild 
type meniscus size at 15-16 and 22-23 months of age compared the 5-6 month mice. The bottom row shows 
mstn-/- mice at 15-16 and 22-23 months of age have an enlarged meniscus (orange arrows) when compared to 
5-6 month counterparts and the age-matched wild type controls. 
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Figure 26. MicroCT Meniscus Bone Volume. Mstn-/-
meniscus bone volume is significantly increased at 
22-23 months of age compared to wild type (WT) control 
mice. With age, the mstn-/- mice meniscus bone volume 
increases significantly from 5-6 to 15-16 to 22-23 
months of age (mo) . The WT meniscus bone does not 
change significantly with age . *p<0.05, **p<0.01 , 
***p<0.0001 
To assess the joint space calcification with a different methodology, 
analysis of the meniscus ossification was measured from the microCT images 
(Figure 26). Although the increment of meniscus ossification showing a 2.9 fold 
greater mstn-/- meniscus bone volume compared to the age-matched control did 
not reach a level of significance at 15-16 months (p=0.06) , the mstn-/- mice show 
a significant 3.2 fold increase at 22-23 months compared to their age-matched 
controls (p<0.0001). While the wild type mice do not show any significant 
changes in meniscal ossification with age, this measure demonstrated a 4 fold 
incr~ase between 5-6 and 15-16 month (p<O.OS) and a 2 fold increase between 
15-16 and 22-23 months of age in mstn-/- mice (p<0.01 ). 
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Ankle MicroCT. 
The qualitative assessment of the ankle at 5-6 months of age showed no 
distinguishable differences between the ankle/tarsal joints of the wild type and 
mstn-/- mice (Figures 27-31). However, the 15-16 month old mstn-/- mice 
showed anatomical abnormalities in the alignment of the calcaneus. In the wild 
type mouse, this bone is naturally positioned in the same plane of the plantar 
surface of the foot (lime arrow); however, the calcaneus of the 15-16 month old 
mstn-/- mice was found close to a 90 angle from the plantar surface of the foot 
(orange arrow), as shown from both the lateral (Figures 28) and the medial 
viewpoints (Figure 29). In addition, the single tarsal bones of the plantar side of 
the hind foot, that were individually distinguishable in the wild type mice, were 
found covered by a calcified mass in both the 15-16 and 22-23 month old mstn-/-
mice (orange arrow, Fig. 30) . The same type of calcification was found shifting 
the position of the talus bone, a bone that lies distal to the tibia and proximal to 
the metatarsals (Fig.27, lime arrow), in the hind-foot of the 15-16 month and 22-
23 month old mstn-/- mice (Fig. 27, orange arrow). 
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Figure 27. MicroCT Anterior View of Hindfoot. The top row shows the wild type ankle and the 
bottow row shows the mstn-/- mice. The three columns demonstrate each increasing age group. 
The mstn-/- mice at 15-16 and 22-23 months of age have calcification that has shifted the 
position of the talus bone and is not seen from the anterior view (orange arrow), when compared 
to the normal position of the talus of the wild type mice (lime arrow). 
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Figure 28. MicroCT Lateral View of Hindfoot. The row is the wild type mouse ankle and the 
bottom row is the mstn-/- mouse ankle. The three columns show each of the three increasing age 
groups. The mstn-/- mice at 15-16 and 22-23 months of age have the calcaneus bone positioned 
approximately 90 degrees from the plantar surface of the foot (orange arrow). The lime arrow points to 
the normal position of the calcaneus in the wild type ankle. 
61 
wild type 
myostatin 
null 
S-6 month 15-16 month 22-23 month 
Figure 29. MicroCT Medial View of Hindfoot. The top row is the wild type mouse ankle and the 
bottom row is the mstn-/- mouse ankle. The three columns show each of the three increasing age 
groups. The mstn-/- mice at 15-16 and 22-23 months of age have the calcaneus bone positioned 
approximately 90 degrees from the plantar surface of the foot (orange arrow). The lime arrow points to 
the normal position of the calcaneus in the wild type ankle. 
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Figure 30. MicroCT Plantar View of Hindfoot. The top is the wild type mouse ankle and 
the bottom row is the mstn-/- mouse ankle. The three columns show each of the three 
increasing age groups. The mstn-/- mice at 15-16 and 22-23 months of age have a calcified 
mass covering the the plantar surface of the tarsal bones of the hind foot (orange arrow). 
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Figure 31. MicroCT Posterior View of Hindfoot. The top row is the wild type ankle and 
the bottom row is the mstn-/- mouse ankle. The three columns show each of the three increasing 
age groups. The mstn-/- mice at 15-16 and 22-23 months of age have calcaneus that is shifted 
approximately 90 degrees from the plantar surface of the hindfoot. 
Manus MicroCT. 
MicroCT analysis of the manus of the 22-23 month-old wild type mice 
show the clear delineation of each of the carpal bones (Fig. 32, left) . In contrast, 
age-matched mstn-/- mice show again the presence of ectopic bone growth that 
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limits the ability to identify clearly each of the carpal bones between the 
radius/ulna and the metacarpal bones (Fig. 32, right). 
WT 
Ulna Radius 
Radius 
Pisiform Lunate 
Triangular Navicular 
Falcifotmis 
Figure 32. MicroCT Ventral View of Manus. The manus of the wild type (left) and mstn-/- (right) mice 
at 22-23 months of age. The mstn-/- mice at 22-23 months of age have ectopic bone growths that limits 
the ability to identify each of the carpal bones. 
Knee Histology 
To further characterize the anatomical differences found in the bones of 
the oldest class of the mstn-/- mice, the knee and ankle joints were isolated from 
the 22-23 month-old mstn-/- and wild type mice, and sectioned for histological 
analysis. The meniscus of the 22-23 month-old mstn-/- mice (Fig. 33 B, orchid 
triangle) is qualitatively larger when compared to the wild type meniscus at the 
same age (Fig. 33 A). The knee of 22-23 month-old mstn-/- mice also showed a 
loss of articular cartilage at the level of the tibial surface of the synovial joint (Fig. 
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33 D, lime triangle). 
A 
c 
Figure 33. Knee Histology. Knee joints of 22-23 month old wild type mice (A, C) 
and mstn-/- (B,D) mice. Notice the mstn-/- mouse knee has an enlarged meniscus 
(B, orchid arrow) and degeneration of the tibial articular cartilage (D, lime arrow) in 
comparison to the age matched wild type control (A & C, respectively). 
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Hindfoot Histology 
A 
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Figure 34. Hindfoot Histology. The tibiotarsal joint of 22-23 month old mstn-/- mice (B) 
exhibit large, random areas of ectopic cartilage growth (orange arrows) compared to the 
age-matched wild type (A). The distorted joint space between the calcaneus and tarsal 
bones of mstn-/- (D) contains ectopic cartilage growth (orange arrows) by morphologic 
assessment when compared to age-matched wild type (C). 
To compete my analysis, I have investigated the morphology of the hind 
foot. Although the 22-23 month-old wild type mice showed clear joint spaces 
between the calcaneus and tarsal bones (Figure 34 A, C), the same anatomical 
region in the 22-23 month-old mstn-/- mice showed increased ectopic 
chondrocyte growth into the joint space of the calcaneus and of the tarsal bones, 
as pointed out by the orange arrows (Fig. 34 B, D). 
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Figure 35. Serum Calcium and Phosphorus. Calcium: There is no difference in calcium levels 
between wild type (WT) and mstn-/- mice. In addition , there are no age-related changes in both 
groups. (A) Phosphorus: WT and mstn-/- mice have no difference in phosphorus levels at each age 
group. With age, the WT serum calcium does not change significantly, but the mstn-/- serum 
phosphorus increases significantly from 5-6 months to 15-16 and 22-23 months. (B) **p<0.01 
To understand if the ectopic ossification observed by microCT was due to 
changes in the calcium and phosphorus serum levels these values were 
measured. The calcium measurements show no significant difference when 
comparing wild type and mstn-/- mice and no effect of aging within each group. 
Similarly, there is no significant difference between mstn-/- and wild type mice 
phosphorus serum levels. The only significant difference measured was the 
increase in serum phosphorus at 15-16 and 22-23 months when compared to the 
5-6 months group in the mstn-/- mice (p<0.01 , respectively). No age-related 
changes were observed in the wild type mice for calcium and phosphorus levels. 
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V. Discussion: 
Summary of Introduction. With the increasing numbers of the aging 
population, it is important to address the issues that may affect "successful 
aging". Aging has been associated with the progressive decline in muscle mass 
and strength which has been associated with disability in the aging population. 16-
1B 
To address this issue, investigators have studied the effect of myostatin 
inhibitors in animal studies and human clinical trials. The loss of myostatin has 
been shown to increase muscle mass?4 Null mutations of myostatin resulted in 
changes in the fiber type and an associated decrease in mitochondria and 
oxidative capacity. 49·50 There is conflicting evidence that shows loss of myostatin 
decreases muscle specific force, but myostatin inhibition increases overall 
muscle strength.45·50·58-60 The type of myostatin inhibition, muscle fiber type 
changes, and muscle strength changes each influence how a myostatin inhibitor 
affects physical performance. At this time, only animal studies with myostatin 
inhibitors have shown a concomitant increase in both mass and strength. In 
addition, the heterozygous myostatin mutation in "bully" whippets enhanced 
racing performance and was another piece of promising evidence toward the use 
of myostatin inhibitors to improve physical performance. 37·83 But improved muscle 
mass and strength may not necessarily lead to a full range of improvement in 
physical function. To understand the effect of long term loss of myostatin on 
physical performance, performed a comprehensive study utilizing 
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measurements defined by Fried et al who described the phenotype of frailty by 
assessing multiple quantitative measurements (e.g . body mass, strength, 
endurance, activity) .6 
Myostatin also has been shown to influence chondrocyte proliferation and 
differentiation. The Gerstenfeld lab found myostatin acts in a particular temporal 
pattern to regulate callus formation during fracture healing.142·143 In addition, 
other studies demonstrate myostatin inhibits both chondrocyte proliferation and 
differentiation. Furthermore, both Smad 2/3 and Smad 1/5 signaling are 
important at various stages of chondrogenic proliferation and differentiation, 
suggesting the correct proportion of each signaling pathway at the correct 
temporal pattern may promote articular cartilage maintenance.136•137·140·141 Thus, 
myostatin may act to maintain the proportion of Smad2/3 and Smad 1/5 signaling 
to regulate chondrocyte proliferation and differentiation and maintain the articular 
cartilage. Understanding how growth factors like myostatin may influence 
articular cartilage is important because with aging there is increased fibrillation , 
changes in the biomechanical properties of cartilage and a decreased 
responsiveness to IFG-1, an anabolic factor. 113-118·129-131 Understanding the 
effect of a growth factor like myostatin is important in the context of aging 
articular cartilage. 
While the major cellular component of articular cartilage is chondrocytes, 
another component of the joint, the meniscus, is composed of fibrochondrocytes, 
cells comparable to chondrocytes and fibrolasts. The meniscus functions in load 
70 
bearing, load transmission, shock absorption, joint stability, joint lubrication and 
joint congruity influences the load on the articular cartilage.156-159 Few studies 
have been performed on the effect of aging or myostatin on menisci 
fibrocartilage. With aging, the ossicles that form within the mouse meniscus 
increase in size. Understanding how myostatin affects mineralization will provide 
insight into possible therapeutic approaches toward the pathological 
mineralization in certain human diseases. The aim was to understand how the 
long term loss of myostatin will affect the joint space and, in particular, the knee 
articular cartilage and menisci fibrocartilage in vivo. 
This study examined if and how the deletion of the two myostatin alleles 
affects clinically relevant measures of physical performance of the mouse and 
the morphology of the joints of the lower limb. My principal goal was to gain 
insight into the possible negative effects of long-term myostatin inhibition. 
Myostatin and Physical Performance 
Since myostatin has been established as a negative regulator of muscle 
mass, there is interest in the development of a myostatin inhibitor to treat 
sarcopenia and other diseases that lead to muscle wasting and degeneration. 
Since limited evidence has been collected on the effects of long term myostatin 
loss, understanding whether the complete deletion of both myostatin alleles has 
deleterious consequences with regards to physical performance is of clinical 
importance if a myostatin inhibitor is used as a therapeutic. In my study, the only 
evidence that the loss of myostatin provides an advantage on physical 
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performance has been the increased grip strength of the 5-6 month old mstn-/-
mice compared to the age-matched control. This finding is consistent with 
previous reports of increased strength in the mstn-/- mice, as well as with 
previous data demonstrating an increase in grip strength with pharmacological 
inhibition of myostatin.47 However, until now, no studies reported data on the grip 
strength of mstn-/- mice. Morissette reported both myostatin and the wild type 
mice lose muscle mass to the same extent with aging. 231 Consistently, my data 
demonstrates this same pattern of muscle loss with aging. However, my results 
illustrate that although the mstn-/- mice maintain an increased muscle mass 
during aging, their grip strength is lower in the older classes. In fact, the mstn-/-
grip strength decreased to the same level as their age-matched controls during 
aging. Thus despite the significantly greater mstn-/- muscle mass in each age 
group compared to their age-matched control, my results demonstrate that a 
larger muscle mass does not maintain a higher level of strength with age. 
Mstn-/- mice not only have greater mass when compared to their age-
matched wild type, they also have a reduced proportion of oxidative muscle 
fibers associated with mitochondria depletion that would suggest increased 
fatigability and exercise intolerance.49•50 Thus, it is not surprising that Savage et 
al. reported that the mstn-/- mice have a lower maximal exercise capacity 
compared to wild type controls at 14 weeks of age, another congruence to what I 
have found in my study. 232 Other studies where myostatin has been inhibited 
using a neutralizing antibody in aged mice demonstrated an improvement of 
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treadmill endurance by 31% compared to the control group. 59 Although the 
improvement was not statistically significant it suggests that myostatin inhibition 
or blockade may benefit exercise capacity. Taken together, data from literature 
was inconclusive on how long-term myostatin blockade affects treadmill 
endurance. My results show that the absence of myostatin reduced treadmill 
endurance when compared to their age-matched control, and that both mstn-/-
and wild type mice experience a significant reduction in exercise capacity with 
aging. My studies thus suggest that long-term myostatin blockade does not aid in 
maintaining exercise capacity, and expand the previous finding by Girgenrath et 
al. who demonstrated that the reduced exercise capacity of the mstn-/- mice 
compared to control is ma.intained as the mice age.49 
Previous studies conducted by Lhotellier et al. reported that the 
ambulatory activity of the C57BL/6 mice are significantly reduced from 5 months 
to 13 months of age, but that there are no significant changes from 13 months to 
25 months of age. 233 My data does not match this prior reported pattern of 
activity. In fact, I show an increase in the horizontal ambulatory activity between 
5 months and 15.:16 month old wild type mice and then a decrease in this 
parameter between 15-16 month and 22-23 month old mice. Interestingly, the 
inverse parabolic pattern of ambulatory activity shown with aging in my study is 
consistent with what has been shown by Lhotellier et al. in other strains of 
mice.233 A number of factors may have affected these results. For example, 
although my study and the Lhotellier study utilized cross-sectional measurements 
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of three independent groups for each age group the methodologies employed to 
measure the ambulatory measurement were different. Also, a number of factors 
that include diet, age, genetics and hypothalamic input could also impact the 
physical activity measurements.234 Unfortunately, neither study was conducted in 
a longitudinal manner, which is the ideal approach to correctly evaluate the 
ambulatory activity. 
Human Implications. My results show that the long term homozygous 
deletion of myostatin does not improve physical performance. Whereas, the 
studies that show the heterozygous deletion for myostatin in "bully" whippets 
enhance racing performance when compared to wild type controls, provides 
evidence that inhibition of myostatin may have the potential to improve physical 
performance. 83 Investigators have also utilized anti-myostatin antibodies to block 
myostatin function, and found increased muscle mass due to hypertrophy and 
increased grip strength.47 The results may imply that precise understanding of 
the dose and duration of myostatin inhibition to treat muscle wasting diseases is 
important to provide improvement in overall physical performance. Thus, the loss 
of myostatin increases muscle mass but there is not a proportional increase in 
overall physical performance. Various clinical trials of myostatin inhibitors have 
found limited efficacy raising the question of whether inhibition of myostatin will 
lead to an effective therapy to improve strength and overall performance. Taken 
together, my results and previous studies predict limited benefits and possible 
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negative effects of the long term inhibition of myostatin to improve human 
physical performance. 
Myostatin and Joint Morphology 
To understand the effect of the loss of myostatin on cartilage and 
fibrocartilage in the joint, I have analyzed the ankle and knee joints of the mstn-/-
mice at the three time points. When compared to the age-matched controls, the 
mstn-/- mice of the two older age groups display an increased meniscus size 
measured in both the flat film x-ray as well as three-dimensional microCT. This 
anatomical evidence was confirmed by histology that showed that the enlarged 
meniscus of mstn-/- mice accumulates fibrocartilage during aging. In addition, my 
microCT data also shows a larger meniscus size on the medial side compared to 
the lateral side of the right knee. These findings suggest that the loss of 
myostatin enlarges both the fibrocartilage meniscus and the ossified regions 
within the meniscus. It is important to note that the meniscus of the rat, guinea 
pig and mouse normally develop "ossicles" which are areas of ossification and 
that both x-ray and microCT assays are able to identify ossicles in the knee 
joint. 151 Previous studies in the guinea pig model show aged-related increases in 
the calcification of the medial meniscus, an effect that could be due to different 
loading forces working in the medial compartment of the meniscus. 235 Several 
lines of evidence led investigators to postulate that differences in loading may 
result in matrix degradation and in the eventual loss of articular cartilage. 236 My 
data also shows loss of articular cartilage at the proximal tibial surface is lost but 
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the articular surface of the distal femur is intact. In addition, there is no loss of 
articular surface of the tarsal bones in the mstn-/- mice hindfoot. From the 
previous studies performed on the relation of myostatin to chondrocytes, I 
expected the loss of myostatin would help maintain the articular cartilage of the 
knee. 145,147 One explanation for the loss of articular cartilage exclusively on the 
tibial surface is increased biochemical shear stress from the enlarged meniscus. 
In animal models where the meniscus are removed there are increased stresses 
on the tibial articular surface. In our model the increase in the size of the 
fibrocartilage and calcification of the meniscus may increase the biomechanical 
shear stress that leads to tibial articular cartilage degeneration. What is still 
unclear is whether the loss of the articular cartilage is a direct consequence of 
the loss of myostatin or if it is secondary to loading changes caused by the larger 
ossified meniscus. 
Similarly, we also do not know if the enlarged meniscus size and loss of 
articular cartilage is directly related to the loss of myostatin itself or secondary to 
the fact that larger muscles might affect the joint, or both. In this regard , a study 
of Schultz et al. described that the increased musculature of the mstn-/- mice 
does not increase the load on their limbs indicating that the changes in the 
meniscus and articular cartilage I found are directly related to the loss of 
myostatin. 
The long term loss of myostatin is shown to result in increased joint space 
ossification in the knee and ankle. Previous studies revealed that the C57BL/6 
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mice, the control group that I used here, can exhibit osteoarthritis of the knee 
joint characterized by enlarged meniscus and osteochondral metaplasia of the 
knee joint.237 The mstn-/- mice in my study have been backcrossed to the 
C57BU6 mice for more than six generations. Thus, the loss of myostatin coupled 
with the spontaneous polyarticular arthroses that occurs in the C57BU6 strain 
could make the mstn-/- mice backcrossed to the C57BU6 strain more susceptible 
to joint pathology associated with aging. Other studies have also demonstrated 
that joint inactivity can lead to cartilage degradation. 87 Although the mstn-/- mice 
in my study do not show clear signs of inactivity, they show nevertheless 
significantly reduced ambulatory motion when compared to their age-matched 
wild type mice. This may be another factor to understand why the knee of the 
mstn-/- mice showed reduced articular cartilage. 
A direct effect of mstn on the cartilage has been suggested in studies 
showing that myostatin may play a role in chondrocyte proliferation and 
differentiation.144•147 In this regard , several studies demonstrated that both Smad 
2/3 and Smad 1/5/8 signaling are involved in the differentiation of the 
chondrocyte. 138 238 239 For example, the stimulation of Smad2 and Smad3 has 
been found to block the terminal differentiation of the chondrocyte, that, as a 
consequence, would result in both reduced differentiation toward hypertrophic 
chondrocytes and mineralization.138 238 From this evidence, I could hypothesize 
that the lack of myostatin reduces the amount of Smad 2/3 signaling which in turn 
results in more differentiation of the chondrocytes toward the hypertrophic stage 
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and more mineralization. This hypothesis is corroborated by the phenotype of the 
Smad3 knockout mice that developed the degeneration of the articular cartilage 
at the older age group as shown by the mstn-/- mice in this study. 238 However, 
the quality of the changes observed in the deletion of Smad3 null mice occurs at 
a younger age than what I have observe in the knee of mstn-/- mice. 
Nevertheless, Smad3 null and mstn-/- mice both show increased joint space 
calcification and degeneration of the articular cartilage. My results show that loss 
of myostatin increases meniscus calcification and suggest that myostatin 
activates Smad 2/3 to inhibit the terminal differentiation and mineralization of 
chondrocytes, and then prevents the enlargement of the ossified meniscus to 
maintain the articular cartilage. However, further studies are necessary to 
understand to what degree myostatin directly affects both articular chondrocytes 
and fibrocartilage. 
The initial observation that drew us to study the possible negative effects 
of chronic myostatin deletion was the loss of plantar flexion in the ankles of the 
male mstn-/- mice. This loss of plantar flexion has been described as a stiffening 
of the ankle and tarsal joints of the hind limbs and labeled ankylosing 
enthesopathy (ANKENT).240 241 The previous reports also describe that the 
ANKENT ankle has cartilage proliferation at the insertions of the joint capsules 
that have been ossified with the highest proportion of ANKENT observed 
between 4 and 8 months of age. 242 ANKENT occurs due to the loss of the 
expression of the ank gene that plays a pivotal role in the mineralization process. 
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Studies suggested that the Ank protein acts as a transmembrane transporter that 
shuttles PPi between the intracellular and extracellular compartments. 206 PPi at 
low concentrations can inhibit mineral formation. 197 The results suggest 
myostatin may maintain ank protein production and the loss of myostatin may 
reduce ank expression and lead to the increased ossification observed in the 
joint space. Coupled together, if the mstn-/- null mice with the stiff ankle joints 
had a reduction in the expression of the ank gene, this could compound the 
amount of mineralization found in the joints of the mice. This suggests that the 
loss of myostatin and the loss of the ank gene product may act synergistically to 
produce more mineralization of the meniscus, the extra ossification in the tarsal 
space of the hindfoot and the carpal bones of the manus. My results display no 
ankylosis in the control C57BL/6 mice in each of the three age groups. Whereas 
the mstn-/- mice were backcrossed in mice with the C57BL/6 background and at 
15-16 months the mstn-/- mice display the decreased plantar flexion suggesting 
possible ankylosis in these ankle joints. What is unclear is what role the loss of 
myostatin played in inducing the ankylosis of the ankle. My data shows a 
significant difference between the control and mstn-/- mice that opens up the 
possibility that the loss of myostatin may play a direct or indirect role in the 
development of AN KENT. 
As previously discussed the studies performed in our lab show that the 
mstn-/- mice exhibit reduced ankle plantar flexion. What is interesting is that the 
reduced ankle plantar flexion is noted only in the male mstn-/- mice and not the 
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female mstn-/- mice. This sexual dimorphism was observed with ankle 
morphology in mstn-/- mice but sexual dimorphism has also been shown in mstn-
/- muscle. A number of studies demonstrated no differential expression of 
myostatin mRNA in men and women.243-245 Other studies show even with similar 
levels of myostatin mRNA in males and females, there are higher myostatin 
protein levels in female compared to male mice. 246 Furthermore, another study 
shows higher ACTRIIB in human women. 245 These results do not definitively 
suggest sexually dimorphic differences in the activation of the myostatin 
pathway. Differences in the processing of myostatin, proteins that bind to 
myostatin or mediate myostatin signal transduction can each influence the 
myostatin activity. 245 The differences in myostatin protein levels and ACTRIIB 
levels may suggest differences in the myostatin activity in men and women. 
Besides noted differences in the pathway of myostatin signaling at the ligand and 
receptor level, previous studies have shown differences in male and female 
mstn-/- muscle. Absence of myostatin increases quadriceps muscle cross 
sectional area in male mstn-/- mice whereas female soleus, plantaris, and 
gastrocnemius muscles are significantly greater compared to their age matched 
wild type controls. 57 Taken together the differences in the muscle weights and 
ankle morphology of male and female mstn-/- mice are phenotypic 
demonstrations of sexual dimorphism related to myostatin deficiency. Further 
studies must be performed to understand if there are differences in myostatin 
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activity between males and femalef that will begin to illuminate the mechanism 
behind these phenotypic differences. 
Human Implications. My data suggests myostatin may play a role in the 
maintenance of the amount of mineralization that occurs in the fibrocartilage 
during aging. Pathological mineralization of fibrocartilaginous tissues is called 
chondrocalcinosis. The most common cause of menisci calcification is calcium 
pyrophosphate dihydrate crystal deposition disease. 247. In addition, human 
osteoarthritic menisci have been shown to calcify more than normal menisci. 248 
Genetic factors, aging, altered responses to growth factors and inflammatory 
cytokines and modifications of the ECM each may contribute to the type of 
crystal formed in the calcification of the cartilage and fibrocartilage. 249 My results 
suggest that myostatin may be a growth factor that is necessary for the menisci 
tissue to resist the accumulation of calcification. There are two types of crystal , 
calcium pyrophosphate dihydrate and calcium hydroxyapatite. Further 
investigation into the type of crystal that is formed in the joint may provide 
evidence that the mstn-/- mice provides possible model to study growth factor 
affect on mineralization to understand pathological mineralization of 
fibrocartilaginous tissues in humans. 
In conclusion , I report that the loss of myostatin is positively associated 
with an increase in muscle mass and strength in the short term. As the mstn-/-
mice age, the overall physical performance measures show deterioration when 
compared to the age-matched controls therefore implying that the use of a 
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myostatin inhibitor to improve muscle function should only be utilized for a short 
I 
duration. Long term studies of myostatin inhibitors may be justified to determine 
the duration these therapeutics should be utilized to provide overall improvement 
in physical performance. 
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